Understanding the Role of Bacterial Biofilm in Antibiotic Resistance: Defensive Strategies and Clinical Challenges
<p id="p1">Bacterial biofilms significantly cause persistent exacerbation of infections in the clinical setting. These groups of microorganisms are highly resistant to host immune responses and conventional antibiotic therapies, whereas they are embedded in an extracellular matrix. This chapter prov...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2025
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/1207913 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p id="p1">Bacterial biofilms significantly cause persistent exacerbation of infections in the clinical setting. These groups of microorganisms are highly resistant to host immune responses and conventional antibiotic therapies, whereas they are embedded in an extracellular matrix. This chapter provides more detailed information on the mechanism of biofilm formation involving key stages of adherence, maturation, and spread, including the composition and structure of a biofilm matrix. This chapter further explores how biofilms contribute to antibiotic resistance, including physical barriers to drug penetration, quorum sensing mechanisms, and adaptive resistance strategies such as genetic adaptation, stress responses, and the formation of persister cells. The role of horizontal gene transfer in the spread of antibiotic resistance within biofilm communities is also discussed. The chapter discusses the clinical challenges posed by biofilm-associated infections, focusing on the challenges of diagnosing and treating chronic and recurrent infections, the role of host factors in biofilm persistence, and the limitations of current therapeutic options. Finally, we address emerging countermeasures to counter resistance mediated by biofilms, such as enzymatic therapies, nanomedicine technologies, natural product-based inhibitors, quorum sensing inhibitory agents, photodynamic and sonodynamic antimicrobial therapy, and combinatorial therapies.</p> |
|---|---|
| ISBN: | 978-0-85466-947-9 |
| DOI: | 10.5772/intechopen.1009440 |